

Program for the Forum Event – market place for *in vitro* tests
At Karolinska Institutet, Stockholm, Sweden 12-14 May 2009

12 May

13.00 **Opening session of The Forum event of Forinvitox and Invitopharma**

Erik Walum, Board member of Silverdal Science Park, Sweden

Welcome presentations

Erica Toft, Silverdal Science Park, Sweden

Antek Wielburski, Expertrådet, Sweden

Introduction to the Forum event: Summary of the Forinvitox and Invitopharma projects

13.30 **Session 1: Available *in vitro* methods with potential to be commercialised**
Chair: Erik Walum

Oliver Engelking, CellSystems® Biotechnologie Vertrieb GmbH, Germany

Human Reconstructed Skin – a success story

14.00 **Meeting/Market time**

Poster session, Exhibition, Match making activities

14.30 **Oral presentations of *in vitro* methods and a panel commenting the methods (I)**

Jef Hooyberghs, Greet Schoeters, Rosette Van Den Heuvel

VITOLENS™: a cell-based alternative to identify skin sensitizers by gene expression

Rodger D. Curren and Marilyn J. Aardema

Development of a New *In Vitro* Genetic Toxicology Model Using Reconstructed Human Skin

Anna Forsby, Johanna Lilja and Heléne Lindegren

The *in vitro* nociception assay for estimation of mild eye irritation

15.30 **Meeting/Market time**

Poster session, Exhibition, Match making activities

16.15 **Oral presentations of *in vitro* methods and a panel commenting the methods (II)**

David Rozzell, Moo-Yeal Lee, Jessica D. Ryan, Jonathan S. Dordick, Douglas S. Clark

Miniaturized Three-Dimensional Cell Culture and Metabolic Enzyme Arrays For High-Throughput Toxicity Assays

Dieter Runge and Anett Ullrich

HEPAC²: Serum-free, standardized and validated (re-usable) primary human hepatocytes for the analysis of xenobiotics

Maya R.Vilà, Agustín Lahoz, Laura Picazo and Myriam Fabre

ISOCYP-TOX: A new ready-to-use concept for *in vitro* evaluation of biotransformation-mediated toxicity

17.15 Meeting/Market time

Poster session, Exhibition, Match making activities

17.45 Oral presentations of *in vitro* methods and a panel commenting the methods (III)

Samuel Constant, Song Huang, Jean Paul Derouette, Mireille Caulfuty

The use of an *in vitro* cell model of the Human Airway Epithelium (MucilAir™) in preclinical development

Marianna D Gaça, David Thorne, Jason Adamson, Eian D Massey

A model of *in vitro* exposure to aerosols at the air-liquid interface

18.15 General discussion

Summing up the day: questions suggested by participants and end with question “do the offers fit with the demand?”

19.00 Dinner/Get together party at Karolinska Institutet

13 May

Bridging the gaps between the inventors and final users

8.30 **Session 2: Testing needs and expectation - managed by IVTIP**
Chair: Bart de Wever

Bart De Wever and Erwin Roggen, IVTIP In Vitro Testing Industrial Platform, Belgium

Bridging the gaps between inventors and final users

Testing needs and expectations: the importance of industrial applicability

Klaus Schroeder, Henkel AG & Co, Germany

The application of the 7th amendment: what models for what use?

Gavin Maxwell, Unilever, UK

Assuring safety without animal testing: Skin sensitisation case study

10.00 **Meeting/Market time**

Poster session, Exhibition, Match making activities

10.45 **Oral presentations of *in vitro* methods and a panel commenting the methods (IV)**

Joachim Wiest¹, M. Brischwein², A.M. Otto³ and B. Wolf^{2,3}

Label-free cell based assays as alternative testing method for toxicity

Sundeep Bhandari

Nikon BioStation CT– an ‘all-in-one’ toxicity testing system solution

José-Enrique O’Connor, Guadalupe Herrera, Laura Díaz and Emilio Barberá-Guillem

The Use of PetakaG2™ Hermetic Cell Culture Containers and Cytomics for Testing of Sustained In Vitro Toxicity (MultiCyttox-LT®)

12.00 **Meeting/Market time**

Poster session, Exhibition, Match making activities

13.00 **Lunch**

14.00 **Session 3: Acceptance and validation - The regulators point of view**
Chair: Odile de Silva, L’Oreal, France

Matthias Peiser, Federal Institute for Risk Assessment, Germany

Even alternative methods regarded “stand alone” replacements of animal tests need to be embedded in testing strategies – a regulators view

Oral presentations of *in vitro* methods and a panel commenting the methods
Denis To Van

Epic® Label-Free System - Applicable throughout the drug discovery process

- 15.00 Meeting/Market time**
Poster session, Exhibition, Match making activities
- 15.45 Oral presentations of *in vitro* methods and a panel commenting the methods (V)**
- Manuela Dahinden-Hase, Jean-Baptiste Fini, Vincent Laudet and Ingemar Pongratz**
SME RECEPTOR – an industry-academia partnership for *in vitro* toxicology testing
- Matthew D. Rand**
A Drosophila embryo platform for high-throughput testing of suspected toxins and bioactive compounds
- Cristina Suñol and Anna Forsby**
Combination of cell based assays determining GABA_A receptor activity and Cell Membrane Potential for *in vitro* testing of neurotoxicity
- Dorothee Hallier-Vanuxeem, Lucie Dehouck, Emmanuel Sevin and Roméo Cecchelli**
Ready-to-use *in vitro* Blood-Brain Barrier model
- 17.30 Session 4: Technology transfer**
Chair: Erica Toft
- Leila Risteli, University of Oulu, Finland**
What to consider in academic technology transfer
- Märit Johansson, Karolinska Institutet Science Park, Sweden**
From brains to business
- Claes Post, Karolinska Institutet Innovation, Sweden**
- Jonas Ekstrand, Actar AB, Sweden**
Actar - Commercializing Science, a Hands-on Story
- 20.00 Dinner at Haga Park (The bus leaves Karolinska Institutet 19.45)**

14 May

9.00

Session 5: Quality and scientific acceptance of alternative methods

Chair: Gavin Maxwell

Sandra Coecke, ECVAM, Italy

Towards relevant and reliable in vitro cell-based test methods for detecting human health effects

Rodger D. Curren, IIVS, Institute for In Vitro Sciences, USA

Human tissue models used for safety testing: scientific, economic and regulatory considerations

Discussion around points to consider when moving towards acceptance, initiated by **Erin H. Hill, Institute for In Vitro Sciences, USA**

Hans H. Lindén, EUFEPS, The European Federation for Pharmaceutical Sciences, Sweden

New safe medicines faster by innovative initiatives and collaboration

11.00

Meeting/Market time

Poster session, Exhibition, Match making activities

11.30

Panel discussion

General questions and aspects with the final question: How useful was the Forum Event?

12.15

Conclusions and closing of the Forum Event

12.30

Lunch